Figure 5 — RIPK2 is an unfavorable prognosis marker and a potential therapeutic target in human kidney renal clear cell carcinoma

Research Paper|Volume 13, Issue 7|pp. 10450–10467

RIPK2 is an unfavorable prognosis marker and a potential therapeutic target in human kidney renal clear cell carcinoma

100%

Figure 5.The difference in estimated immune cell fraction. Distribution plot of estimated immune cell fraction among between RIPK2 high- and low- expression samples. Statistical significance was determined by the Wilcoxon rank-sum test.